Niagen says preclinical Nature Communications study links CD38 to NAD+ decline

Niagen Bioscience announced publication of independent preclinical research in Nature Communications led by Sichuan Agricultural University, examining CD38 as a driver of age-related NAD+ decline, lower NAD+ levels in placental tissue of older mothers, and NAD+ restoration with nicotinamide riboside (NR) improving pregnancy outcomes.